Business Segments:
a) North America Formulations (40% of Q4 FY26 revenue):
Co. ranked 3rd among US generic companies
by generic TRx, a gain of 2 positions over the
last 4 years. During Q4 FY26, 6 new products were launched, 3 ANDAs filed, and 9 ANDAs approved. For full year FY26, 30 ANDAs were filed and 26 approved including 6 tentative approvals. Cumulative filings stand at 508
and cumulative approvals at 435 including
26 tentative.^[1]
b) India Formulations Business (24% of Q4 FY26 revenue):^[2]
The company has 10 brands with value above Rs 1,000 mn, 24 between Rs 500-1,000 mn, and 35 between INR 250-500 mn. Key product launches in Q4 FY26 include Tishtha - world's first biosimilar of Nivolumab, Anyra - India's first indigenously developed biosimilar of Aflibercept 2 mg, and Semaglutide injection under three brands - Semaglyn, Mashema, and Alterme.
c) Consumer Wellness (20% of Q4 FY26 revenue):^[3]
The company operates in 2 different segments viz. personal care segment comprising the Nycil and Everyuth brands and food and nutrition segment through the brands Glucon-D, Sugar Free, Complan, and Nutralite.^[4]
Glucon-D holds ~59% market share (Rank 1), Nycil holds ~33% (Rank 1), Sugar Free holds ~96% (Rank 1). In the Everyuth range, Scrub holds ~49% share (Rank 1) and Peel Off holds ~75% (Rank 1), while Facial Cleansing holds ~8% (Rank 5). Complan holds 4% fat spread share (Rank 4). Nutralite is Rank 1 in fat spread by company estimates. RiteBite and Max Protein are Rank 1 in Nutrition & Protein Bar and Protein Cookies & Chips by company estimates.
d) International Markets Formulations (11% of Q4 FY26 revenue):
The company's international markets division comprises of the Emerging Markets (selected territories in Asia Pacific, Middle East, Africa and Latin America) and Europe (France, Spain and the UK). In emerging markets, co. adopted a focused, therapy led approach, tailoring the offerings to meet the needs of specific markets. In Europe, focus remains on broadening the portfolio and enhance the market coverage.